For decades, medicine has accepted a heartbreaking truth: Alzheimer’s can only be slowed down, never reversed. But at Santa Clara-based TrueBinding Inc., founder Ke Hong and his team are on a mission to rewrite that narrative. By targeting a key protein behind neuroinflammation, they are pioneering a novel investigational approach designed to explore what traditional therapies couldn’t—the potential for restoring cognitive function and independence.
Founded in 2016, TrueBinding has distinguished itself in the competitive field of drug development by focusing on Galectin-3 (Gal-3), a protein implicated in numerous diseases, including neurodegenerative disorders. The company’s lead candidate, TB006, is a first-in-class, high-affinity monoclonal antibody designed to address a broad spectrum of dementias, including Alzheimer’s. By reducing neuroinflammation and preventing the formation of toxic protein aggregates, TB006 aims to go beyond the limitations of traditional therapies that primarily slow decline. Early clinical observations suggest it may hold potential for genuine cognitive improvement or even reversal—positioning TrueBinding as an innovator in neuroscience and a source of hope for patients and families.
The name ‘TrueBinding’ reflects the company’s core scientific philosophy: their antibody truly binds to the target protein with high affinity, ensuring a precise and effective therapeutic response. This level of precision is not just a technical achievement but a testament to the meticulous research and development that drives the company forward.
“Hearing a patient say that our treatment ‘gave my life back’ is incredibly rewarding,” shares Ke Hong, whose vision for TrueBinding is grounded in tangible human impact. Patients have reported regaining cherished activities once lost to illness—playing the piano, gardening, and reclaiming everyday independence—creating moments of profound significance for families…